OSE Immunotherapeutics Cash Flow Statement

Financials in millions EUR. Fiscal year is January - December.

Millions EUR. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Net Income	-32.52	37.45	-23	-17.76	-16.85
Depreciation & Amortization	1.21	0.95	3.53	3.54	2.66
Other Amortization	-	2.36	-	-	-
Stock-Based Compensation	-	2.09	1.75	2.73	2.94
Other Operating Activities	2.23	6.24	-0.98	-3.38	0.64
Change in Accounts Receivable	-	-3.16	-0.58	-	-
Change in Accounts Payable	-	-1.57	0.76	-	-
Change in Income Taxes	-	-2.62	-0.22	-0.24	-0.33
Change in Other Net Operating Assets	2.49	6.71	-1.02	-3.14	1.03
Operating Cash Flow	-26.6	48.44	-19.76	-18.25	-9.92
Capital Expenditures	-0.45	-0.08	-0.02	-0.27	-0.47
Investment in Securities	-	-46.83	-0.28	-	-
Other Investing Activities	36.11	-	-0.22	0.3	-0.36
Investing Cash Flow	35.66	-46.91	-0.51	0.03	-0.83
Long-Term Debt Issued	-	2.11	5.02	12.06	15.28
Long-Term Debt Repaid	-7.2	-6.25	-3.36	-1.8	-0.59
Net Debt Issued (Repaid)	-7.2	-4.15	1.67	10.26	14.69
Issuance of Common Stock	-	1.16	11.66	-	0.27
Other Financing Activities	-0.6	-0.47	-	0.01	-
Financing Cash Flow	-7.79	-3.46	13.32	10.27	14.96
Miscellaneous Cash Flow Adjustments	-	-	-0	-	-
Net Cash Flow	1.27	-1.93	-6.95	-7.96	4.21
Free Cash Flow	-27.05	48.36	-19.78	-18.53	-10.39
Free Cash Flow Margin	-1518.01%	57.97%	-888.19%	-101.22%	-39.50%
Free Cash Flow Per Share	-1.23	1.89	-1.01	-1.00	-0.57
Cash Interest Paid	-	0.47	-	-	-
Levered Free Cash Flow	-16.71	33.19	-11.18	-9.07	-4.21
Unlevered Free Cash Flow	-16.71	35.17	-9.8	-8.21	-3.69
Change in Working Capital	2.49	-0.64	-1.05	-3.38	0.69

Source: S&P Global Market Intelligence. Standard template. Financial Sources.